Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2023-10-16 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
2023年员工持股计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed summary of the 2023 Employee Stock Ownership Plan (员工持股计划) draft for Chongqing Boteng Pharmaceutical Technology Co., Ltd. It includes comprehensive information about the plan's purpose, principles, participants, funding sources, stock sources, scale, duration, lock-up period, changes, termination, and rights of participants. The document is lengthy (over 10,000 characters) and contains substantive content about the employee stock ownership plan, which is a form of capital/financing update related to company fundraising and capital structure changes. It is not an announcement of a report, nor a regulatory filing or certification. It is not a general annual or quarterly report, nor a management or governance report. The focus on employee stock ownership plans aligns with Capital/Financing Update filings. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-10-16 Chinese
关于为子公司向银行申请外汇授信和贷款提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding the provision of guarantees for its subsidiaries' bank loans and foreign exchange credit facilities. It details the guarantee amounts, the subsidiaries involved, the purpose of the guarantees, and the board's approval. There are no financial statements or detailed financial performance data presented, nor is this a report or transcript. The document is a regulatory announcement about financing guarantees, which fits the category of Capital/Financing Update (CAP). The document length is short (2592 characters), and it is not merely announcing the publication of a report but providing substantive information about financing guarantees. Therefore, the correct classification is CAP with high confidence.
2023-10-16 Chinese
公司章程（2023年10月）
Governance Information Classification · 100% confidence The document is titled "公司章程" which translates to "Articles of Association" or "Company Bylaws". It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, and other governance matters. It references Chinese company law and securities law, and includes detailed chapters on shareholders, board of directors, management, financial accounting, and meeting procedures. There is no indication that this is a financial report, earnings release, or announcement. Instead, it is a governance document outlining the internal rules and structure of the company. Therefore, the document fits the category of Governance Information (CGR). The document length (15,000 characters) and content confirm it is a full governance document, not a brief announcement or summary.
2023-10-16 Chinese
独立董事关于公司2023年员工持股计划及管理办法的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors of Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding the company's 2023 employee stock ownership plan and its management measures. It references relevant laws, regulations, and company articles, and concludes with approval to submit the plan to the 2023 fourth extraordinary general meeting for consideration. The document is short (910 characters) and is a formal opinion or statement rather than a full report or announcement of voting results. It does not contain financial statements or detailed financial data. It is not a report publication announcement or regulatory filing. The content fits best under Regulatory Filings (RNS) as it is a compliance-related document providing an independent opinion on a corporate governance matter related to employee stock plans.
2023-10-16 Chinese
第五届董事会第二十次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Chongqing Porton Pharmaceutical Technology Co., Ltd. It details decisions on loan applications, employee stock ownership plans, amendments to the company charter, and the scheduling of a shareholders meeting. The document includes voting results and references to further detailed announcements on a regulatory information website. The content is focused on board meeting decisions and governance matters rather than financial results, audit opinions, or shareholder voting outcomes. It is not a full annual or interim report, nor a call transcript or earnings release. The document is a board/management information announcement about board resolutions and governance actions. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 3268 characters, which is consistent with a detailed board meeting announcement rather than a full report.
2023-10-16 Chinese
关于2020年限制性股票激励计划预留授予的第三个解锁期限制性股票解锁上市流通的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding the unlocking and listing of restricted shares under the 2020 restricted stock incentive plan. It includes specifics about the number of shares unlocked, the conditions met for unlocking, board and supervisory approvals, and changes in shareholding structure. The document is not a financial report, earnings release, or management discussion but rather a formal announcement about share unlocking related to stock incentives. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share unlocking and stock incentive plan execution, not a full report or financial statement. The document length (6237 characters) and detailed content support this classification with high confidence.
2023-09-28 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.